Switch theme
Sign up to access all valuation multiples
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
2003
n/a
LTM Revenue $112M
LTM EBITDA -$50.6M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bio-Thera Solutions has a last 12-month revenue (LTM) of $112M and a last 12-month EBITDA of -$50.6M.
In the most recent fiscal year, Bio-Thera Solutions achieved revenue of $103M and an EBITDA of -$55.6M.
Bio-Thera Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bio-Thera Solutions valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $112M | XXX | $103M | XXX | XXX | XXX |
| Gross Profit | $79.4M | XXX | $71.3M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$50.6M | XXX | -$55.6M | XXX | XXX | XXX |
| EBITDA Margin | -45% | XXX | -54% | XXX | XXX | XXX |
| EBIT | -$65.6M | XXX | -$68.8M | XXX | XXX | XXX |
| EBIT Margin | -59% | XXX | -67% | XXX | XXX | XXX |
| Net Profit | -$65.9M | XXX | -$70.8M | XXX | XXX | XXX |
| Net Margin | -59% | XXX | -69% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $23.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Bio-Thera Solutions's stock price is CNY 26 (or $4).
Bio-Thera Solutions has current market cap of CNY 10.9B (or $1.5B), and EV of CNY 11.1B (or $1.5B).
See Bio-Thera Solutions trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.5B | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Bio-Thera Solutions has market cap of $1.5B and EV of $1.5B.
Bio-Thera Solutions's trades at 14.9x EV/Revenue multiple, and -27.7x EV/EBITDA.
Equity research analysts estimate Bio-Thera Solutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bio-Thera Solutions has a P/E ratio of -23.0x.
See valuation multiples for Bio-Thera Solutions and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 13.8x | XXX | 14.9x | XXX | XXX | XXX |
| EV/EBITDA | -30.5x | XXX | -27.7x | XXX | XXX | XXX |
| EV/EBIT | -23.5x | XXX | -22.4x | XXX | XXX | XXX |
| EV/Gross Profit | 19.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -23.0x | XXX | -21.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -60.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBio-Thera Solutions's last 12 month revenue growth is 20%
Bio-Thera Solutions's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Bio-Thera Solutions's rule of 40 is -22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bio-Thera Solutions's rule of X is 5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Bio-Thera Solutions and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | -45% | XXX | -54% | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -22% | XXX | -34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 105% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 136% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Thera Solutions acquired XXX companies to date.
Last acquisition by Bio-Thera Solutions was XXXXXXXX, XXXXX XXXXX XXXXXX . Bio-Thera Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Bio-Thera Solutions founded? | Bio-Thera Solutions was founded in 2003. |
| Where is Bio-Thera Solutions headquartered? | Bio-Thera Solutions is headquartered in China. |
| Who is the CEO of Bio-Thera Solutions? | Bio-Thera Solutions's CEO is Ms. Cui Hua Liu. |
| Is Bio-Thera Solutions publicy listed? | Yes, Bio-Thera Solutions is a public company listed on SHG. |
| What is the stock symbol of Bio-Thera Solutions? | Bio-Thera Solutions trades under 688177 ticker. |
| When did Bio-Thera Solutions go public? | Bio-Thera Solutions went public in 2020. |
| Who are competitors of Bio-Thera Solutions? | Similar companies to Bio-Thera Solutions include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bio-Thera Solutions? | Bio-Thera Solutions's current market cap is $1.5B |
| What is the current revenue of Bio-Thera Solutions? | Bio-Thera Solutions's last 12 months revenue is $112M. |
| What is the current revenue growth of Bio-Thera Solutions? | Bio-Thera Solutions revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Bio-Thera Solutions? | Current revenue multiple of Bio-Thera Solutions is 13.8x. |
| Is Bio-Thera Solutions profitable? | Yes, Bio-Thera Solutions is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bio-Thera Solutions? | Bio-Thera Solutions's last 12 months EBITDA is -$50.6M. |
| What is Bio-Thera Solutions's EBITDA margin? | Bio-Thera Solutions's last 12 months EBITDA margin is -45%. |
| What is the current EV/EBITDA multiple of Bio-Thera Solutions? | Current EBITDA multiple of Bio-Thera Solutions is -30.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
